The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

J Cardiovasc Transl Res. 2023 Oct;16(5):999-1009. doi: 10.1007/s12265-023-10390-w. Epub 2023 May 1.

Abstract

It has been shown that SGLT2 suppresses atherosclerosis (AS). Recent studies indicate that autophagy widely participates in atherogenesis. This study aimed to assess the effect of canagliflozin (CAN) on atherogenesis via autophagy. Macrophages and ApoE - / - mice were used in this study. In macrophages, the results showed that CAN promoted LC3II expression and autophagosome formation. Furthermore, the cholesterol efflux assay demonstrated that CAN enhanced cholesterol efflux from macrophages via autophagy, resulting in lower lipid droplet concentrations in macrophages. The western blot revealed that CAN regulated autophagy via the AMPK/ULK1/Beclin1 signaling pathway. CAN resulted in increased macrophage autophagy in atherosclerotic plaques of ApoE - / - mice, confirming that CAN could inhibit the progression of AS via promoting macrophage autophagy. The current study found that CAN reduced the production of atherosclerotic lesions, which adds to our understanding of how SGLT2 inhibitors function to delay the progression of AS.

Keywords: Atherosclerosis; Autophagy; Macrophage; SGLT2 inhibitor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins E / metabolism
  • Apolipoproteins E / pharmacology
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / metabolism
  • Atherosclerosis* / prevention & control
  • Autophagy
  • Canagliflozin / metabolism
  • Canagliflozin / pharmacology
  • Cholesterol
  • Macrophages / metabolism
  • Mice
  • Plaque, Atherosclerotic* / pathology
  • Sodium-Glucose Transporter 2 Inhibitors* / metabolism
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology

Substances

  • Canagliflozin
  • Sodium-Glucose Transporter 2 Inhibitors
  • Cholesterol
  • Apolipoproteins E